Teva Pharmaceutical's 15-min chart: MACD Death Cross, Bollinger Bands Narrowing, KDJ Death Cross.

Based on the 15-minute chart of Teva Pharmaceutical, the MACD has triggered a death cross, Bollinger Bands have narrowed, and KDJ has also triggered a death cross as of September 3, 2025, at 15:15. This technical analysis suggests that the stock price has the potential to continue declining, with a decrease in the magnitude of stock price fluctuations, and a shift in momentum towards the downside, which could result in further price decreases.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has seen significant changes in its institutional holdings and analyst ratings in recent quarters. The stock has been the subject of several upgrades and downgrades, with a consensus rating of "Buy" and an average price target of $24.71 [1].

In the first quarter of 2025, Driehaus Capital Management LLC significantly reduced its stake in Teva by 99.4%, selling nearly 3 million shares and leaving them with just 18,631 shares valued at $286,000 [1]. Meanwhile, Brooklyn Investment Group increased its stake by 403.4%, owning 5,009 shares valued at $77,000 after acquiring an additional 4,014 shares [1]. Several other institutional investors, including Golden State Wealth Management LLC, New Age Alpha Advisors LLC, and Banque Cantonale Vaudoise, also made new investments in Teva's stock [1].

Analysts have been optimistic about Teva's prospects, with Goldman Sachs and JPMorgan Chase raising their price targets for the stock [1]. However, technical indicators suggest a potential shift in momentum. As of September 3, 2025, at 15:15, the MACD has triggered a death cross, Bollinger Bands have narrowed, and the KDJ has also triggered a death cross [2]. These technical signals suggest that the stock price has the potential to continue declining, with a decrease in the magnitude of stock price fluctuations and a shift in momentum towards the downside, which could result in further price decreases.

Teva Pharmaceutical Industries has reported strong earnings, with $0.66 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.02 [1]. The company's revenue was $4.18 billion for the quarter, slightly missing estimates but showing a positive return on equity of 46.10% and a negative net margin of 0.95% [1]. Despite these positive earnings, the technical indicators suggest a potential downturn in the stock price.

Investors should closely monitor Teva Pharmaceutical Industries' stock price and technical indicators to make informed investment decisions. The company's strong earnings and positive analyst ratings are promising, but the technical indicators suggest a potential decline in the stock price.

References:
[1] https://www.marketbeat.com/instant-alerts/filing-driehaus-capital-management-llc-cuts-stock-position-in-teva-pharmaceutical-industries-ltd-teva-2025-09-01/
[2] https://www.marketbeat.com/instant-alerts/filing-teva-pharmaceutical-industries-ltd-teva-shares-acquired-by-retirement-planning-co-of-new-england-inc-2025-09-01/